MAY 14, 2015 06:00 AM PDT

Next-generation sequencing for BRCA1 and BRCA2 mutation testing

  • Director, Head of Biological research content, Qiagen, Inc.
      Dr. Devgan is the head of the Biological Research Content, QIAGEN. He received his Ph.D. in molecular biology and conducted post-doctoral research at Harvard Medical School before moving to the biotechnology industry. He received his MBA from the University of Wurzburg in Germany and has spent many years as a scientist in developing new technologies and products clinical and translational research.


    Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other cancers. Studying mutations along the entire length of these genes will bring us closer to winning the fight against cancer, so every base of BRCA1 and BRCA2 is important to your cancer research. QIAGEN recently launched the GeneRead DNAseq BRCA1/2 Targeted Panel covering 100% of the coding region and intron-exon junctions, enabling you to analyze every base of the BRCA1 and BRCA2 genes. This presentation will cover the development, experimental verification, NGS workflow, and data interpretation associated with the BRCA1/2 targeted DNA sequencing panel. Learning objectives: 1. Critical success factors for BRCA1 and BRCA2 testing 2. Challenges and solutions for BRCA1 and BRCA2 testing in FFPE samples 3. Application of targeted sequencing strategy for BRCA genes in blood and FFPE samples

    Show Resources
    Loading Comments...